Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test - Laine,K.; Tybring,G.; Härtter,S.; Andersson,K.; Svensson,J.O.; Widen,J.; Bertilsson,L. (Clin Pharmacol Ther, 2001)